Indication
Treatment of osteoporosis in postmenopausal women at increased risk of fracture (see section 5.1). A reduction in the risk of vertebral fractures has been demonstrated, efficacy on femoral neck fractures has not been established.
Loading your page…
Osteoporosis, Postmenopausal
Marketing Authorisation Holder: Atnahs Pharma Netherlands B.V.
EMA Authorisation: 23/02/2004
INN: ibandronic acid
AI Drug & Interaction Analysis
Free account required
Ask Osler about Bonviva: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.